METHODS: We performed a retrospective multicenter study. From April 1999 to April 2018, all consecutive patients who underwent ER for SCC with tumor infiltration beyond the muscularis mucosae were included.
RESULTS: A total of 137 ER were analyzed. The overall nodal or metastatic recurrence-free survival rate at 5 years was 88% and specific recurrence-free survival rates at 5 years with and without adjuvant therapy were, respectively, 97.9% and 79.1% (p = 0.011). Independent factors for nodal and/or distal metastatic recurrence were age (HR = 1.075, p = 0.031), Sm infiltration depth > 200 µm (HR = 4.129, p = 0.040), and the absence of adjuvant CRT or surgery (HR = 11.322, p = 0.029).
CONCLUSIONS: In this study, adjuvant therapy is associated with a higher recurrence-free survival rate at 5 years after non-curative ER. This result suggests this approach may be considered as an alternative to surgery in selected patients.
方法:我们进行了一项多中心回顾性研究。从1999年4月至2018年4月,包括所有因SCC而接受ER且肿瘤浸润超过粘膜肌层的患者。
结果:共分析了137例ER。5年的总淋巴结或无转移复发生存率为88%,有或没有辅助治疗的5年的无复发生存率为,分别,97.9%和79.1%(p=0.011)。淋巴结和/或远端转移复发的独立因素是年龄(HR=1.075,p=0.031),Sm入渗深度>200µm(HR=4.129,p=0.040),和没有辅助CRT或手术(HR=11.322,p=0.029)。
结论:在这项研究中,在非治愈性ER后5年,辅助治疗与较高的无复发生存率相关.该结果表明,这种方法可以被认为是某些患者手术的替代方法。